Abstract

Broadband ultraviolet B (BB-UVB) phototherapy has demonstrated efficacy in the treatment of cutaneous disorders including psoriasis, atopic dermatitis, uremic pruritus and idiopathic pruritus. In the last decade, there has been a rapidly escalating process of replacing BB-UVB phototherapy units with narrowband ultraviolet B (NB-UVB) equipment, as studies have demonstrated that NB-UVB (ranging from 311 mm to 312 nm) is more efficacious in the treatment of psoriasis. Nevertheless, it is important to recognize the efficacy of BB-UVB phototherapy in the treatment of uremic pruritus, idiopathic pruritus, eosinophilic folliculitis and other inflammatory pruritic conditions. Furthermore, as highlighted in this report, there is a small but significant proportion of psoriasis and atopic dermatitis patients who do not tolerate NB-UVB but demonstrate an excellent clinical response to BB-UVB. It is critical for dermatologists to recognize the role of BB-UVB as a complement to NB-UVB phototherapy for patients who cannot tolerate or experience an inadequate therapeutic response from NB-UVB.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.